AstraZeneca has been in focus in recent weeks mainly due to the COVID-19 vaccine, the approval of which is being discussed in the UK these days. Experts are still anticipating approval from the country’s authorities this year. But the Swedish-British pharmaceutical company has a few other irons in the fire – and some of them are not going as hoped.
The US regulatory authority FDA has now postponed a decision on the drug Roxadustat for three months to March and has requested further data from the pharmaceutical company Astrazeneca and its cooperation partner FibroGen. Which additional details are required is open. The new potential approval date would be March 20th.
The analysts at Goldman Sachs did not expect this, but they are also not surprised. In any case, they are negative for the AstraZeneca share and continue to give a sell recommendation. The price target of the stock experts for the AstraZeneca share also remains unchanged and stands at 6,400 British pence.
In XETRA trading, the stock is currently losing 1.51 percent to EUR 81.53.
Livestream on December 14th, 2020 from 6 p.m .:
With Hans-Werner Sinn, former President of the Ifo Institute: Corona and the miraculous increase in money in Europe
– Here is the stream! –